Search company, investor...

NanoString Technologies

nanostring.com

Founded Year

2003

Stage

IPO | IPO

Total Raised

$104.64M

Date of IPO

6/26/2013

Market Cap

0.49B

Stock Price

10.35

Revenue

$0000 

About NanoString Technologies

NanoString Technologies is a provider of life science tools for translational research and developer of molecular diagnostics. The company's nCounter Analysis System delivers highly multiplexed, direct profiling of individual molecules in a single reaction without amplification. The nCounter Analysis System offers a cost-effective way to profile gene transcripts, copy number variations, or miRNAs simultaneously with high sensitivity and precision. The company's technology enables a variety of basic research and translational medicine applications, including biomarker discovery and validation. NanoString is also developing the technology for use in molecular diagnostics. In June 2013, NanoString Technologies went public with a valuation of $145 million.

Headquarters Location

530 Fairview Avenue North Suite 2000

Seattle, Washington, 98109,

United States

206-378-6266

Missing: NanoString Technologies's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: NanoString Technologies's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing NanoString Technologies

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

NanoString Technologies is included in 4 Expert Collections, including Medical Devices.

M

Medical Devices

11,691 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.

C

Cancer

3,710 items

Products/services that analyze tumor-derived biomarkers (ctDNA, CTCs, exosomes) in blood/urine/other non-invasive liquid specimens to detect cancer earlier, guide treatment, and monitor progress. *Data fields manually updated as new information becomes available.'

O

Omics

1,267 items

Companies involved in the capture, sequencing, and/or analysis of genomic, transcriptomic, proteomic, and/or metabolomic data

H

Health IT

7,901 items

NanoString Technologies Patents

NanoString Technologies has filed 52 patents.

The 3 most popular patent topics include:

  • Biotechnology
  • Molecular biology
  • Genetics
patents chart

Application Date

Grant Date

Title

Related Topics

Status

5/14/2019

1/10/2023

Molecular biology, DNA, Polymerization reactions, Genetics, Biotechnology

Grant

Application Date

5/14/2019

Grant Date

1/10/2023

Title

Related Topics

Molecular biology, DNA, Polymerization reactions, Genetics, Biotechnology

Status

Grant

Latest NanoString Technologies News

NanoString Releases Single Cell Spatial Transcriptomics Dataset Highlighting Data Quality of CosMx Spatial Molecular Imager

Jan 19, 2023

01/19/2023 | 06:01am EST Message : *Required fields New liver tissue dataset highlights high sensitivity and specificity of CosMx system, and the biological power of spatially analyzing 1000 RNA targets NanoString Technologies, Inc. (NASDAQ: NSTG), a leading provider of life science tools for discovery and translational research, today announced a public release of new data generated by the CosMx™ Spatial Molecular Imager (SMI). This data was generated from formalin-fixed paraffin-embedded (FFPE) human liver samples and showcases the best-in-class data quality of the CosMx SMI. The dataset highlights CosMx SMI’s high sensitivity, with the capability to detect and quantify an average of 1,150 transcripts per cell and to maximize biological insights by detecting 676 unique genes. The dataset also represents CosMx SMI’s high specificity, with more than 99% of identified counts on targeted genes. CosMx SMI enables high-resolution imaging of more than 1,000 RNA and over 64 protein analytes within morphologically intact whole tissue sections. The CosMx instrument allows researchers to visualize and quantify gene and protein expression at single cell and subcellular resolutions within both fresh frozen and FFPE tissue samples. Using a multi-modality approach, including protein imaging, CosMx SMI delivers best-in-class cell segmentation. This high-plex in situ analysis also enables researchers to perform cell typing, cell state, functional, and cell-cell interaction analyses in a single experiment generating high-resolution cell atlases. NanoString used the CosMx SMI to characterize liver FFPE tissue from normal and hepatocellular carcinoma patients. The CosMx human liver data provides subcellular expression map of 1,000 genes and a single cell tissue atlas that categorizes each cell in the tissue as one of 18 unique cell types. The complete dataset consists of over 800,000 single cells and ~700 million transcripts, and a single-cell tissue atlas across a ~180 mm2 area of liver tissue. The high-plex analysis provided deep insight into the cell and tissue changes that occur in cancer, including infiltration of diverse immune cells. “The CosMx SMI provides researchers with the ability to profile more genes than any other single cell in situ imager. As this dataset demonstrates, the market-leading plex of CosMx yields high sensitivity and specificity. The AtoMx™ Spatial Informatics Platform (SIP) enables powerful insights into the rich datasets generated by the CosMx,” said Joe Beechem, chief scientific officer, NanoString Technologies. This spatial in situ imaging and molecular data is released in an open-source AtoMx SIP export format, which can be accessed through NanoString’s website ( https://nanostring.com/products/cosmx-spatial-molecular-imager/human-liver-rna-ffpe-dataset/ ). This will allow analyses by the research community and facilitate open-source informatics tools development for the class-leading AtoMx SIP. The AtoMx SIP is a flexible cloud-based informatics platform that provides the secure, scalable storage and analysis that spatial biology researchers need to drive their workflow from study design to peer-reviewed publication. AtoMx SIP is compatible with both the CosMx SMI platform and the GeoMx® Digital Spatial Profiler (DSP). A cloud-based platform obviates the need for laboratories to invest in their own costly informatics infrastructure and reduces spatial biology analysis compute times from days to hours. Users have the flexibility to apply a pre-defined data analysis pipeline, to customize these pipelines using their own code, and to access open-source tools developed by the bio-informatics community. The CosMx SMI and AtoMx SIP are the newest products in the company's industry-leading spatial analysis portfolio, joining the GeoMx DSP. The GeoMx DSP is a fully-automated spatial profiler allowing multi-cellular analysis of whole transcriptome for both human and mouse applications, and customizable for other species. To learn more about NanoString's CosMx Spatial Molecular Imager, visit www.nanostring.com/CosMx About NanoString Technologies, Inc. NanoString Technologies, a leader in spatial biology , offers an ecosystem of innovative discovery and translational research solutions, empowering our customers to map the universe of biology. The GeoMx® Digital Spatial Profiler, cited in more than 190 peer-reviewed publications, is a flexible and consistent solution combining the power of whole tissue imaging with gene expression and protein data for spatial whole transcriptomics and proteomics from one FFPE slide. The CosMx™ Spatial Molecular Imager is an FFPE-compatible, single-cell imaging platform powered by spatial multiomics enabling researchers to map single cells in their native environments to extract deep biological insights and novel discoveries from one experiment. The AtoMx Spatial Informatics Platform is a cloud-based informatics solution with advanced analytics and global collaboration capabilities, enabling powerful spatial biology insights anytime, anywhere. At the foundation of our research tools is our nCounter® Analysis System, cited in more than 6,500 peer-reviewed publications, which offers a secure way to easily profile the expression of hundreds of genes, proteins, miRNAs, or copy number variations, simultaneously with high sensitivity and precision. For more information, visit www.nanostring.com . NanoString, NanoString Technologies, the NanoString logo, CosMx, GeoMx, AtoMx and nCounter are trademarks or registered trademarks of NanoString Technologies, Inc. in various jurisdictions. View source version on businesswire.com: https://www.businesswire.com/news/home/20230119005290/en/ © Business Wire 2023

NanoString Technologies Frequently Asked Questions (FAQ)

  • When was NanoString Technologies founded?

    NanoString Technologies was founded in 2003.

  • Where is NanoString Technologies's headquarters?

    NanoString Technologies's headquarters is located at 530 Fairview Avenue North, Seattle.

  • What is NanoString Technologies's latest funding round?

    NanoString Technologies's latest funding round is IPO.

  • How much did NanoString Technologies raise?

    NanoString Technologies raised a total of $104.64M.

  • Who are the investors of NanoString Technologies?

    Investors of NanoString Technologies include Threshold Ventures, Clarus, Accelerator Life Science Partners, OVP Venture Partners, GE Ventures and 10 more.

  • Who are NanoString Technologies's competitors?

    Competitors of NanoString Technologies include Cofactor Genomics, DxTerity Diagnostics, Biomatrica, HTG Molecular Diagnostics, ProteinSimple and 11 more.

Compare NanoString Technologies to Competitors

Biocom Logo
Biocom

Biocom works to drive public policy, build a network of industry leaders, create access to capital, introduce STEM education programs, and create value-driven purchasing programs.

Harvard Bioscience Logo
Harvard Bioscience

Harvard Bioscience acquires and distributes laboratory equipment and products for companies and institutions in the life sciences field.

O
Ocimum Biosolutions

Ocimum Biosolutions is a life sciences RnD enabling company with three focus areas, BioIT (LIMS / Bioinformatics), BioMolecules, and BioResearch. Ocimum aims to deliver end to end genomic products and services out of three strategic locations worldwide, Indianapolis (United States), IJsselstien (The Netherlands), Hyderabad (India).

Shamrock Structures Logo
Shamrock Structures

Shamrock Structures is a structural proteomics company focused on assisting pharmaceutical and biotechnology clients reduce the time it takes to advance from protein targets to drugs by offering integrated services in structural proteomics including protein cloning, expression, purification and crystallization.

P
ProteoPlex

Proteoplex is a spinout of Incyte Genomics and aims to provide the scientific community with key functional genomic and proteomic tools and services in the areas of Gene Expression, Protein Expression and Cell-Based Assays. The proteomics product addresses a major barrier in defining the function of proteins in cells; how to quickly and cheaply test thousands of samples for the presence of a particular set of proteins. This protein product will be closely followed by the launch of gene expression products to solve a similar barrier in the genomics market; how to quickly and cheaply interrogate thousands of samples against a defined set of important genes.

Solidus Biosciences Logo
Solidus Biosciences

Solidus Biosciences is a company that received a STTR Phase II grant for a project entitled: Development of a Lead Optimization Chip for Drug Discovery. Their award is funded under the American Recovery and Reinvestment Act of 2009 and their project will address further development and commercialization of a multi-enzyme lead optimization chip (Multizyme Chip) for high-throughput generation of lead compound analogs coupled with cell-based screening for the rapid identification of biologically active derivatives. Such a capability directly impacts a key bottleneck in drug discovery; namely, the efficient optimization of lead compounds to develop drugs with optimal pharmacological properties. Solidus Biosciences, Inc. proposes to combine six biocatalysis with pharmacological screening to provide rapid identification of biologically active compounds against cell-specific targets, which is a new paradigm for lead optimization. Moreover, the Multizyme Chip platform will be well-suited for lead optimization in related industries, including agrochemicals, cosmetics, and cosmeceuticals. The Solidus technology will thus improve the competitiveness and efficiency of the pharmaceutical, cosmetics, and chemical industries, and will serve as a rich source of new and improved commercial products. The broader impacts of this research are the advances that Solidus Biosciences will achieve toward generating better and safer drugs, reducing the cost to develop these drugs, and increasing the overall efficiency of the pharmaceutical industry. Solidus will generate Multizyme Chips for purchase by pharmaceutical and biotechnology companies to facilitate their lead optimization programs, particularly those involving natural product-derived and complex synthetic small molecule leads. Cryopreservation techniques developed in Phase II will enable the sale of chips and chip-handling devices produced during Phase I, and will allow seamless penetration of the Solidus technology platform into the company's target markets. Solidus Biosciences is a company that received a STTR Phase I grant for a project entitled: Development of a Lead Optimization Chip for Drug Discovery. Their research project aims to develop a new method for generating lead compounds by using enzymatic modification of compound sets. Availability of new methodology to generate biologically active compounds from existing molecules may enhance the success of the drug discovery process and may lead to the discovery of new and useful therapeutics. Solidus Biosciences is a company that received a STTR Phase I grant for a project entitled: High-Throughput RNAi Screening of Mammalian Cells. Their research project aims to develop a system for the rapid screening of siRNAs that can inhibit genes involved in cellular responses such as hyperosmotic stress that can affect pathways of high commercial importance, including protein production. Use of hyperosmotic stress as a proof of concept system will demonstrate the feasibility of high-throughput RNAi screening and will at the same time yield results that can be used to improve monoclonal antibody production in commercial and laboratory settings Production of biopharmaceuticals such as antibodies is exquisitely responsive to the culture conditions under which the cells are grown and thus can be improved through optimizing such settings, which in turn, would affect the genes involved in the specific synthetic pathways of interest. Development of a rapid methodology to identify inhibitory RNA molecules that can inhibit genes that adversely affect yield would be of significant importance to pharmaceutical companies that produce protein therapeutics and may result in a lowering of the const of these therapeutic entities.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.